Chemomab TherapeuticsCMMB
Market Cap: $27.2M
About: Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
Employees: 20
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
18% more capital invested
Capital invested by funds: $2.08M [Q1] → $2.44M (+$366K) [Q2]
7% more funds holding
Funds holding: 14 [Q1] → 15 (+1) [Q2]
0% more ownership
Funds ownership: 0.94% [Q1] → 0.94% (+0%) [Q2]
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
Research analyst outlook
We haven’t received any recent analyst ratings for CMMB.
Financial journalist opinion
Based on 3 articles about CMMB published over the past 30 days